Scientists at University of California, San Diego, discovered that repressing a single protein in fibroblasts is enough to convert them into functional neurons. This finding has far-reaching implications for developing new treatments for neurodegenerative diseases like Alzheimer's and Parkinson's.
Researchers identified a fusion between FGFR3 and TACC3 genes in human glioblastoma samples, which promoted tumor growth and progression in a mouse model. The fusion protein escaped regulation by miR-99a, indicating its potential as a prognostic marker and drug target for glioblastoma treatment.
A new study challenges previous views on miR-205's function in breast cancer. Research found that miR-205 is overexpressed in transformed cells and contributes to the abnormal morphology of acini. The findings suggest miR-205 can act as an oncogene, promoting cell growth or inhibiting apoptosis.
UT Southwestern researchers identified microRNA miR-15 as a regulator of the heart's ability to regenerate, with potential therapeutic applications. By understanding this molecular mechanism, scientists may be able to control the heart's regenerative process and develop new treatments for cardiovascular disease.
Researchers found that microRNA-26a suppresses melanoma cell growth while leaving healthy cells unharmed. Reintroducing microRNA-26a to melanoma cell lines led to a marked decrease in cancer cell survival, suggesting it as a potential therapeutic target for melanoma treatment.
Researchers report on the therapeutic potential of microRNAs in cancer therapy and their role as potential biomarkers for early cancer detection. The stability of miRNAs in body fluids makes them suitable for non-invasive malignancy detection methods, offering exciting opportunities for revolutionizing diagnostics and screening.
Researchers at UNC discovered that the hepatitis C virus binds with microRNA miR-122 to protect itself, promoting viral replication. This interaction presents a promising target for new drugs to treat the infection.
Researchers identified miR-181a as a molecule linked to aggressive breast cancer forms. Elevated levels of miR-181a prevented metastasis and extended mouse lifespans in test models.
Researchers found a link between a specific gene variant and lower triglyceride levels, as well as higher HDL cholesterol. Carriers of the variant tend to have lower risk of cardiovascular disease, particularly when consuming more polyunsaturated fat.
Sanford-Burnham researchers found that two microRNA families, let-7 and miR-18, regulate germ layer formation by dampening the TGFβ signaling pathway. This discovery provides a paradigm for whole-genome screening and its use in identifying molecular signals controlling complex biological processes.
Reintroducing miR-200c to aggressive triple-negative breast cancer cells restores sensitivity to anoikis, causing the cells to self-destruct. This approach shows promise as a less toxic alternative to chemotherapy.
A new gene called miR-941 has been found to play a crucial role in human brain development and may have contributed to the evolution of language and tool use. This unique gene emerged between six and one million years ago, making it a significant discovery in understanding what makes humans different from apes.
LncRNAs have been found to regulate gene expression in various diseases, including brachydactyly and HELLP syndrome. Additionally, research on obesity has shown that early genetic intervention can rescue mice from obesity-induced metabolic disorders. Furthermore, editing mistakes in miR-376 cluster have been linked to invasive brain tu...
Researchers at Moffitt Cancer Center have discovered that microRNA miR-214 plays a critical role in regulating ovarian cancer stem cell properties. The study found that miR-214 induces the expression of a stem cell transcription factor (Nanog), leading to chemoresistance and potentially serving as a therapeutic target for ovarian cancer.
Researchers identified miR-34a's role in fatty liver disease and Type II diabetes. Blocking miR-34a improved metabolic outcomes, including decreased liver fat and improved blood glucose levels.
Scientists at Virginia Tech and the University of Texas Southwestern Medical Center found that two mini-molecules called microRNAs can help stem the nation's obesity epidemic. The discovery suggests that treatments targeting these two specific microRNAs may help regulate cellular metabolism and increase energy expenditure, leading to r...
A*STAR scientists have identified a potential drug target, miR-138, that can prevent the progression and relapse of glioblastoma multiforme, a deadly form of brain tumour. Depleting this biomarker with antimiR-138 led to complete destruction of cancer cells in vitro.
MMV has developed a framework to evaluate the risk of resistance for its antimalarial compounds. The framework includes cross-resistance testing and selection experiments in the laboratory, measuring the likelihood of parasite mutations that confer resistance.
Scientists are exploring ways to target cancer cells by attacking defective genes before protein production, leveraging micro RNAs (miRNAs) and their interactions with messenger RNAs. miR-7 and miR-128 affected pathways related to cell adhesion, EMT, and cellular replication in ovarian cancer cells.
Researchers have discovered a genetic process that can restore function to a defective protein responsible for cystic fibrosis. By manipulating a specific microRNA network, they were able to partially restore the protein's function and increase its production.
Researchers at Ohio State University found that liver cancer cells lose the ability to produce glucose due to microRNA-23a overexpression. Suppressing miR-23a might reverse this process and offer a new treatment for hepatocellular carcinoma, the most common form of liver cancer.
Researchers found that miR-122 modulates fat and cholesterol metabolism and has a tumor suppressive function in hepatocytes. A mouse model with MiR-122 loss of function also promoted breast tumor growth by differentially regulating ERα and ERβ.
A new study suggests that loss of microRNA-122 leads to liver cancer and that restoring this molecule may slow tumor growth. The researchers developed a model where mice lack miR-122 and develop liver cancer, which can be treated by restoring the molecule.
A recent study found that miR-122 is involved in modulating fat and cholesterol metabolism in the liver. Additionally, it may have a tumor suppressive function in hepatocytes, suggesting its potential as a therapeutic target for hepatocellular carcinoma. The molecule's role in liver homeostasis has also been highlighted.
Directly targeting microRNA-125b to block androgen receptor activity represents a novel approach for treating castrate-resistant prostate cancer. The study provides new insight into the mechanism of miR-125b regulation of castrate-resistance prostate cancer.
Researchers are developing a new oral multiple sclerosis drug that targets the molecule miR-326, which stimulates the production of immune system mediators. The drug aims to inhibit miR-326 and block the production of Th17 cells, potentially offering a more convenient treatment option for patients.
Researchers discovered that silencing miR-33 reduces bile transporters and improves liver toxicity caused by statins. This breakthrough may lead to treatment options for those with BRIC and statin side effects, including improved bile metabolism and reduced cholestasis.
Researchers at Ohio State University found that the loss of microRNA-125b (miR-125b) shuts down normal cell metabolism and enables cancer cells to proliferate. The study reveals a new mechanism by which chronic lymphocytic leukemia (CLL) develops, providing potential targets for new drugs.
Researchers have discovered that high levels of protein EYA3 are associated with a poor response to chemotherapy in Ewing's sarcoma patients. Lowering EYA3 levels may help increase the effectiveness of existing therapies and improve outcomes.
Researchers identified significant variation in microRNA expression within single tumors, highlighting the importance of sampling multiple tumor zones. This finding may explain conflicting previous results and emphasizes the need for personalized medicine approaches.
Scientists have discovered that the controlled release of microRNA miR-675 slows down placental growth before birth, regulating a key factor in healthy pregnancy. This finding has important implications for understanding how environmental signals and diet may influence fetal development.
Researchers at Brigham and Women's Hospital have identified a microRNA called miR-181b that can reduce the inflammatory response responsible for diseases like sepsis. The findings suggest that higher levels of miR-181b may be protective against sepsis and other inflammatory diseases.
Researchers at Ohio State University Comprehensive Cancer Center identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study found that overexpression of miR-3151 leads to poor treatment responses and shorter survival periods, independent of other gene mutations.
Researchers develop miR-TRAP, a new method to directly identify microRNA targets in cells. This technique allows scientists to understand the roles microRNAs play in human development and disease, bridging a gap in the RNA field.
A team led by Martin Friedlander at Scripps Research Institute has received a $10.2 million grant to develop a new treatment strategy for diabetic retinopathy, macular degeneration, and other vision disorders. The approach targets a strand of micro-RNA that promotes abnormal blood vessel growth.
The Society for Experimental Biology and Medicine (SEBM) has awarded ten young investigators for their groundbreaking research in the field of biomedical sciences. The awardees include Jie Xie and Zachary Berwick from Indiana University, who investigated human adipose-derived stem cells and coronary microvascular dysfunction respectively.
A US study demonstrates that hepatitis C virus (HCV) replication can be limited by innate immune responses in murine cells. Inactivating these pathways and expressing entry factors enables infection and support of HCV replication.
Researchers have identified a microRNA, miR-625-3p, that can accurately diagnose malignant pleural mesothelioma with an accuracy of 82.4%. Additionally, high-dose radiotherapy has shown promising response rates for patients with disease confined to one side of the chest.
Researchers have identified a genetic signature for regulation of IL-13, a key immune hormone involved in allergic reactions. MicroRNA miR-375 is regulated by IL-13 and plays a role in asthma and eosinophilic esophagitis (EoE), a severe food allergy.
Researchers found that lengthy spaceflight affects cardiovascular responses, but the intensive exercise routines on these missions keep mechanisms well-prepared for return to Earth. The study tested six astronauts on long-term missions aboard the International Space Station.
African Americans in Georgia have poorer survival rates from cancer compared to national averages, with racial disparities widening rural areas. The study found that MIRs were higher for African Americans than whites across all cancer sites, particularly prostate, cervical, and oral cancers.
Researchers have identified microRNA-155 as a molecule that controls the severity of acute graft-versus-host disease in leukemia patients who receive bone-marrow transplants. Reducing or blocking miR-155 expression decreases GVHD severity and increases survival, suggesting a new strategy for treating the condition.
Two tiny molecules, miR-21 and miR-29b, have been found to strengthen the aorta during bulge growth, reducing abdominal aortic aneurysms in mice. The team believes this could lead to a new treatment for the disease.
A new study found that a microRNA named miR-279 acts through the JAK/STAT pathway to regulate locomotor activity rhythms, maintaining normal patterns of wakefulness and sleep. The researchers identified a protein called Upd as a target of miR-279, which displays daily oscillations in its secretion.
Researchers have discovered a biomarker, miR-375, that can predict the life-threatening nature of head and neck cancer tumors. The study found that patients with lower levels of miR-375 are more likely to experience aggressive disease progression.
Research reveals that a poor maternal diet can affect fat storage in later life, increasing the risk of type 2 diabetes and other age-related diseases. The team identified a molecule called miR-483-3p as the key player in this process, which suppresses a protein called GDF3.
A new study shows that targeting a specific microRNA, miR-221, can prolong the lives of mice with human liver cancer. The treatment also boosted activity of tumor-suppressor genes in these animals.
Researchers discovered that increased production of microRNA miR-21 stimulates progressive muscle deterioration in a mouse model of Duchenne muscular dystrophy. Inhibiting miR-21 reduced collagen levels and prevented fibrogenesis in diseased animals, suggesting it as a potential therapeutic target.
The hepatitis C virus has evolved a unique relationship with the liver's miR-122 microRNA to stabilize its RNA and promote efficient replication. A new experimental antiviral drug works by binding to and sequestering this microRNA, destabilizing viral genome and accelerating degradation.
Researchers at Ohio State University found that normal cells in tumors can enhance cancer cell growth after losing a tumor suppressor gene called Pten. The study suggests interrupting signals between normal cells and cancer cells as a new approach to treating breast cancer.
Researchers have discovered a microRNA, miR-520, that suppresses NFkappaB and TGF-b signaling pathways in breast cancer cells. This finding suggests that miR-520 may act as a tumor suppressor and could lead to new treatment options for ER-negative breast cancer.
Dana-Farber Cancer Institute researchers have identified a mechanism that triggers inflammation in the liver and transforms normal cells into cancerous ones. They demonstrated that a particular micro-RNA, miR-124, can be harnessed to treat or prevent liver cancer.
A new study provides clear procedures for collecting and analyzing microRNAs, significantly improving diagnostic accuracy. Researchers developed measures to overcome interfering activities and improved the sensitivity of miRNA detection by up to 30-fold, enabling faithful quantitation of miRNA abundance in body fluids.
Researchers found that specific microRNAs are up-regulated in obese individuals with healthy periodontium and non-obese subjects with periodontal disease. The study suggests microRNA modulation may play a role in modulating inflammatory pathways within periodontal tissues.
Researchers have discovered a new therapy that increases good cholesterol and lowers triglycerides, showing promise in combating cardiovascular disease. The treatment, which targets microRNA-33, has been shown to increase HDL cholesterol and lower triglyceride levels in non-human primates.
Researchers at NYU Langone Health have identified microRNA-33a/b as a novel therapeutic target to suppress triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C). The study shows that inhibition of miR-33a/b markedly suppresses triglycerides and causes a sustained increase in HDL-C.
The study discovered that pericytes can stimulate new blood vessels and aid in the recovery of a heart attack by transferring microRNAs to endothelial cells. This novel mechanism could lead to the development of new treatments for cardiovascular disease.
Researchers have developed a new imaging method, spatial light interference microscopy (SLIM), that can measure cell mass with high accuracy. SLIM offers insights into the debated problem of whether cells grow at a constant rate or exponentially.
A study published in Genes & Development reveals a specific RNA cluster, miR-17~92, plays a key role in the growth of retinoblastoma, a rare form of childhood eye cancer. The researchers found that overexpression of this microRNA cluster helps cells proliferate despite the loss of tumor-suppressing protein Rb.
Researchers discovered that specific microRNAs play a crucial role in melanoma metastasis by suppressing the immune system and promoting cell invasion. The study found that these miRNAs can serve as biomarkers for more aggressive tumors, suggesting new therapeutic targets for battling the deadliest form of skin cancer.